GLP-1 analogues have contributed significantly to the treatment of T2DM, as these therapies result in better glycemic control through a variety of mechanisms.
It is well known that glucagon acts on the liver to stimulate glycogenolysis and gluconeogenesis. In addition to this, glucagon also regulates amino acid metabolism and ureagenesis and has an effect on hepatic fat metabolism.
The liver is the primary site of insulin clearance from plasma and excessive accumulation of fat in the liver significantly impairs the process.
Levels of the proinflammatory adipokine leptin are increased in obesity, and this hormone has been called “an active player in the development of NAFLD”.
Oxidative stress is an important pathological event in the progression of NAFLD towards NASH.
HEADQUARTERS IN UPPSALA, SWEDEN:
SE-754 50 UPPSALA, SWEDEN
© COPYRIGHT 2017
PHONE + 46 18 57 00 70
FAX + 46 18 57 00 80
Visit us on social media:
facebook.com/mercodia twitter.com/Mercodia linkedin.com/company/mercodia-ab plus.google.com/113076055858025990989